Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 5/20 | 0.56 |
| ▸ | HTR2A | P28223 | 3/20 | 0.56 |
| ▸ | HTR2B | P41595 | 3/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.56 |
| ▸ | HRH2 | P25021 | 2/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.56 |
| ▸ | HRH1 | P35367 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.56 |
| ▸ | HTR6 | P50406 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | HTR5A | P47898 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1446951 | 0.99 | HTR7 (0.57) | HTR7HTR2AHTR2BADRA2ACHRM2 | |
| Hydrochloric Acid SCHEMBL9860099 | 0.98 | HTR7 (0.56) | HTR7HTR2AHTR2BADRA2ACHRM2 | |
| SCHEMBL2058761 | 0.88 | HRH1 (0.57) | HTR7HTR2AHTR2BADRA2ACHRM2 | |
| Hydroxyzine SCHEMBL10930632 | 0.88 | HRH1 (0.78) | HTR7HTR2AHTR2BADRA2ACHRM2 | |
| Hydrochloric Acid SCHEMBL10930701 | 0.87 | HRH1 (0.58) | HTR7HTR2AHTR2BADRA2ACHRM2 | |
| SCHEMBL7628259 | 0.87 | HTR7 (0.48) | HTR7HTR2AHTR2BADRA2ACHRM2 | |
| SCHEMBL3988740 | 0.86 | HTR7 (0.58) | HTR7HTR6HRH3BCL2BAK1 | |
| Hydrochloric Acid SCHEMBL10930120 | 0.86 | HTR7 (0.47) | HTR7HTR2AHTR2BADRA2ACHRM2 | |
| SCHEMBL219876 | 0.85 | HRH1 (0.59) | HTR7HTR2AHTR2BADRA2ACHRM2 | |
| Hydrochloric Acid SCHEMBL5113101 | 0.84 | HTR7 (0.57) | HTR7HTR6KCNH2HRH3BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122021-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl)-4-[(4-methylphenyl)sulfonyl) piperazine | COSSEMENT ERIC (BE) | 2004-06-24 | — | — | US | claimed |
| EP-0955295-B1 | Therapeutically active levorotatory and dextrorotatory 1-((4-chlorophenyl)phenylmethyl) piperazines | UCB SA (BE) | 2004-05-19 | — | — | EP | claimed |
| EP-1413307-A1 | Therapeutically active levorotatory and dextrorotatory 1-(4-chlorophenyl)phenylmethyl piperazines | UCB S.A. (BE) | 2004-04-28 | — | — | EP | claimed |
| US-20030204089-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | COSSEMENT ERIC (BE) | 2003-10-30 | — | — | US | claimed |
| EP-0955295-A1 | Therapeutically active levorotatory and dextrorotatory 1-((4-chlorophenyl)phenylmethyl) piperazines | UCB, S.A. (BE) | 1999-11-10 | — | — | EP | claimed |
| EP-0617028-A1 | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulfonyl piperazine | U C B, S.A. (BE) | 1994-09-28 | — | — | EP | claimed |
| US-20110172425-A1 | NOVEL WATER BASED PROCESS FOR THE PREPARATION OF SUBSTITUTED DIPHENYLMETHYL PIPERAZINES | CALYX CHEMICALS AND PHARMACEUTICALS PVT. LTD. (IN) | 2011-07-14 | — | — | US | disclosed |
| US-20070142400-A1 | For treatment of allergies; antihistamines | COSSEMENT ERIC | 2007-06-21 | — | — | US | disclosed |
| US-20060252934-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl]piperazine | COSSEMENT ERIC | 2006-11-09 | — | — | US | disclosed |
| US-20060229319-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl)-4-[(4-methylphenyl)sulfonyl] piperazine | COSSEMENT ERIC | 2006-10-12 | — | — | US | disclosed |
| US-20060229320-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | GOBERT JEAN | 2006-10-12 | — | — | US | disclosed |
| US-20050182070-A1 | Method for the treatment of allergic conditions | GOBERT JEAN (BE) | 2005-08-18 | — | — | US | disclosed |
| US-20050182069-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | COSSEMENT ERIC (BE) | 2005-08-18 | — | — | US | disclosed |
| US-20030105113-A1 | Enantiomers of 1-[ (4-chlorophenyl) phenylmethyl ] -4-[ (4-methylphenyl) sulfonyl ] piperazine | COSSEMENT ERIC (BE) | 2003-06-05 | — | — | US | disclosed |
| US-20030105112-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | COSSEMENT ERIC (BE) | 2003-06-05 | — | — | US | disclosed |
| US-6436942-B1 | ADMINISTERING THE ANTIHISTAMINE, CETIRIZINE, PRODUCED FROM THIS INTERMEDIATE OF HIGH OPTICAL PURITY | UCB, S.A. (BE) | 2002-08-20 | — | — | US | disclosed |
| EP-0617028-B1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl)sulfonyl] piperazine | UCB SA (BE) | 2000-06-14 | — | — | EP | disclosed |
| EP-0955295-A1 | Therapeutically active levorotatory and dextrorotatory 1-((4-chlorophenyl)phenylmethyl) piperazines | UCB, S.A. (BE) | 1999-11-10 | — | — | EP | disclosed |
| US-5478941-A | Useful in treatment of asthma, allergies, inflammation and anxiety; antihistaminic activity | U C B, S.A. (BE) | 1995-12-26 | — | — | US | disclosed |
| EP-0617028-A1 | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulfonyl piperazine | U C B, S.A. (BE) | 1994-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122021-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl)-4-[(4-methylphenyl)sulfonyl) piperazine | RPLP1, QDPR, RPLP2 | HTR7 169/4885HTR2A 34/4885HTR2B 108/4885 |
| US-20050182070-A1 | Method for the treatment of allergic conditions | CMA1, HRH2, HRH4 | HTR7 308/4885HTR2A 126/4885HTR2B 133/4885 |
| US-20030105113-A1 | Enantiomers of 1-[ (4-chlorophenyl) phenylmethyl ] -4-[ (4-methylphenyl) sulfonyl ] piperazine | RPLP1, QDPR, PRLHR | HTR7 163/4885HTR2A 30/4885HTR2B 110/4885 |
| US-20030204089-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | RPLP1, QDPR, PRLHR | HTR7 163/4885HTR2A 30/4885HTR2B 110/4885 |
| US-20070142400-A1 | For treatment of allergies; antihistamines | HRH2, HRH1, HRH4 | HTR7 337/4885HTR2A 140/4885HTR2B 162/4885 |
| US-20050182069-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | QDPR, COMT, PRLHR | HTR7 108/4885HTR2A 25/4885HTR2B 64/4885 |
| US-20030105112-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | RPLP1, QDPR, RPLP2 | HTR7 212/4885HTR2A 49/4885HTR2B 128/4885 |
| US-20110172425-A1 | NOVEL WATER BASED PROCESS FOR THE PREPARATION OF SUBSTITUTED DIPHENYLMETHYL PIPERAZINES | ALK, WIZ, HACL2 | HTR7 1254/4885HTR2A 403/4885HTR2B 781/4885 |
| US-20060229319-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl)-4-[(4-methylphenyl)sulfonyl] piperazine | HRH2, HRH1, HRH4 | HTR7 135/4885HTR2A 10/4885HTR2B 27/4885 |
| US-20060229320-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | HRH2, CMA1, HRH4 | HTR7 296/4885HTR2A 22/4885HTR2B 58/4885 |
| US-20060252934-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl]piperazine | QDPR, PRLHR, COMT | HTR7 102/4885HTR2A 24/4885HTR2B 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.